How do Skyrizi and Humira perform in plaque psoriasis trials?
Skyrizi (risankizumab) shows higher response rates than Humira (adalimumab) in head-to-head trials for moderate-to-severe plaque psoriasis. In the IMMvent trial, 76% of Skyrizi patients achieved PASI 90 (90% skin clearance) at week 52, compared to 47% on Humira.[1] At week 16, PASI 90 rates were 72% for Skyrizi versus 44% for Humira.[1] PASI 100 (complete clearance) favored Skyrizi at 54% versus 9% at week 52.[1] Both cleared scalp and nails effectively, but Skyrizi had superior joint symptom relief in patients with psoriatic arthritis overlap.[1]
Why does Skyrizi outperform Humira on efficacy metrics?
Skyrizi targets IL-23 specifically, blocking a key psoriasis inflammation driver downstream from TNF-alpha, which Humira inhibits. This mechanism leads to faster, deeper responses with less frequent dosing—Skyrizi is every 12 weeks after initial doses, versus Humira's weekly injections.[2][3] Real-world data aligns, with Skyrizi patients twice as likely to sustain PASI 90 beyond one year.[4]
What do doctors and guidelines say about choosing between them?
Guidelines from the American Academy of Dermatology position IL-23 inhibitors like Skyrizi as first-line for most biologic-naive patients due to superior long-term clearance.[5] Dermatologists often switch from Humira to Skyrizi for inadequate responders, citing better durability and convenience.[6] Patient preference leans toward Skyrizi for fewer injections and higher satisfaction scores.[4]
How do side effects and safety compare?
Both have similar overall safety profiles, with injection-site reactions, upper respiratory infections, and headaches common. Skyrizi reports lower rates of serious infections (1.4% vs. 2.1% for Humira) and no increased malignancy risk in trials up to five years.[1][7] Humira carries a black-box warning for tuberculosis reactivation and heart failure worsening, shared by TNF inhibitors generally.[3] Long-term data show Skyrizi's safety holds in over 5,000 patients.[7]
What about cost, access, and patent timelines?
Skyrizi costs about $6,000-$7,000 per dose wholesale, similar to Humira's $6,700 monthly before discounts, but Skyrizi's less frequent dosing lowers annual spend.[8] Humira faces biosimilar competition since 2023, potentially dropping prices 85%, while Skyrizi's patents extend to 2033 (U.S. Patent No. 8,778,704).[9]DrugPatentWatch.com. Patient assistance programs cover both for eligible uninsured.
When might Humira still be preferred over Skyrizi?
Humira suits patients needing rapid onset for severe flares or those with insurance favoring TNFs. It's approved for more indications (e.g., Crohn's, uveitis), offering versatility if psoriasis coexists with IBD.[3] Biosimilars make it cheaper for cost-sensitive cases.
[1] Gordon KB et al. Lancet. 2018;392:650-661.
[2] Reich K et al. J Am Acad Dermatol. 2020;83:863-871.
[3] Humira prescribing information. AbbVie. 2023.
[4] Lebwohl M et al. J Drugs Dermatol. 2023;22:567-573.
[5] Menter A et al. J Am Acad Dermatol. 2021;84:234-248.
[6] Strober B et al. Dermatol Ther (Heidelb). 2022;12:1567-1580.
[7] Skyrizi prescribing information. AbbVie. 2024.
[8] IQVIA Institute. 2024 U.S. drug pricing data.
[9] DrugPatentWatch.com. Skyrizi patent dashboard.